Collections

Filters ​

  • Collection |

    Immunotherapies have revolutionised therapy for some cancers.In particular, antibodies that block signals that reduce inhibition of T cell function, have led to complete regressions that are maintained for years, in melanoma and now in bladder cancer and non-small cell lung cancer. Recently, chimeric antigen receptor T cells have produced remarkable responses in patients who have failed multiple other therapies. In parallel with therapeutic trials, many other mechanisms and pathways are being investigated in optimising these treatments.Many of these areas are covered in this collection of papers and reviews.

  • Focus |

    Immunotherapies against immune checkpoint inhibitors have rapidly changed treatment paradigms for several major cancers including melanoma, non-small cell lung cancer and bladder cancer. In this selection of articles we highlight the expression of one of the key pathways, PD-L1, and its potential for selecting patients for therapy.

  • Focus |

    See what scientists world-wide are reading! View the most popular minireviews published in BJC.

  • Focus |

    Exploiting and targeting the immune system are emerging as important therapeutic strategies for cancer.Here we bring together recent papers covering experimental models as well as early phase human clinical studies and highlighting novel CTL epitopes, cellular therapy approaches, cancer vaccines, and anti-tumour immunoRNases.

  • Focus |

    There are over 500 new anti-cancer drugs in various stages of clinical development. The BJC remains an important venue to report clinical trial results. The following is a brief selection of recently published trials with promising new drugs to watch.

  • Focus |

    Metastatic melanoma has been among the most difficult cancers to treat with limited and highly toxic treatment options. Recent advances in immune checkpoint inhibitors and molecularly targeted drugs have profoundly changed the life expectancy and quality of life of patients with metastatic melanoma. Therapeutic options are broadening for these patients and these recent articles in the BJC illustrate the trajectory of current research.

  • Focus |

    Tumour MiRNAs - the focus of these articles is on changes during treatment, detection in urine or detection in tumours and how they relate to outcome and prognosis in a wide range of tumour types - pancreatic, prostate, bladder, colon cancer, melanoma, multiple myeloma and peripheral nerve sheath tumours. Though there is a major focus on genetic changes and the targeting of cancer treatment, microRNAs are another significant epigenetic mechanism for regulation in tumour biology that needs to integrated with the genetic profiles.